Hematology

Platelet Clotting

Primary hemostasis — how platelets form the initial plug at vascular injury

Primary hemostasis is the rapid platelet-driven response to vascular injury — adhesion, activation, aggregation. Platelets are anucleate fragments (~1.5-3 μm) shed from megakaryocytes; normal count 150-400 × 10^9/L; lifespan 7-10 days. When endothelium breaks, exposed collagen and von Willebrand factor (vWF) capture platelets via GP Ib-IX-V receptor. Activation flips procoagulant phospholipids outward, releases dense granules (ADP, serotonin) and α-granules (vWF, fibrinogen, growth factors), and activates GP IIb/IIIa receptors that bind fibrinogen, cross-linking platelets. The platelet plug is then stabilized by the coagulation cascade producing fibrin (secondary hemostasis). Antiplatelet drugs target this pathway — aspirin (irreversible COX-1), P2Y12 inhibitors (clopidogrel, ticagrelor), GP IIb/IIIa antagonists.

  • Normal platelet count150-400 × 10^9/L
  • Platelet lifespan7-10 days
  • OriginMegakaryocytes in bone marrow (TPO-driven)
  • Adhesion receptorGP Ib-IX-V (binds vWF)
  • Aggregation receptorGP IIb/IIIa (binds fibrinogen)
  • Aspirin mechanismIrreversible COX-1 inhibition (TXA2 reduced)

Interactive visualization

Press play, or step through manually. The visualization is yours to drive — try it before reading on.

Open visualization fullscreen ↗

Watch the 60-second explainer

A condensed visual walkthrough — narrated, captioned, under a minute.

Why platelet clotting matters

  • Hemostasis. First line of defense against bleeding from injury.
  • Cardiovascular disease. Antiplatelets prevent MI and stroke recurrence.
  • Stents. DAPT (dual antiplatelet therapy) prevents in-stent thrombosis.
  • Bleeding disorders. Von Willebrand disease, ITP, drug effects need recognition.
  • Critical illness. DIC, HIT, TTP all involve dangerous platelet abnormalities.
  • Surgery. Antiplatelet management balances bleeding vs. thrombosis risk.
  • Pregnancy. Gestational thrombocytopenia, HELLP, ITP all need management.

Common misconceptions

  • Low platelet count means bleeding. Function matters too — many drugs cause platelets to malfunction at normal counts.
  • Heparin causes bleeding. HIT causes clotting — never give platelets, use alternative anticoagulant.
  • Aspirin works for hours. Effect lasts 7-10 days — through entire platelet lifespan.
  • Platelet transfusion always helps. Contraindicated in TTP and HIT — worsens thrombosis.
  • Thrombocytopenia equals ITP. Many causes; differential matters because some need different treatment.
  • VWD is rare. Most common inherited bleeding disorder (~1% of population, often subclinical).

Frequently asked questions

How does von Willebrand factor work?

vWF is a large multimeric glycoprotein synthesized by endothelial cells (Weibel-Palade bodies) and megakaryocytes. Under high shear stress (arterioles), vWF unfolds and exposes A1 domain that binds platelet GP Ib-IX-V — the only receptor that captures fast-flowing platelets. vWF also carries factor VIII, protecting it from degradation. Von Willebrand disease (most common inherited bleeding disorder, 1% prevalence) presents with mucocutaneous bleeding, prolonged PFA-100, normal platelet count. Treatment: desmopressin (DDAVP) releases stored vWF; vWF concentrates for severe cases.

What is the platelet activation pathway?

Adhered platelets undergo shape change (discoid to spiny sphere via cytoskeletal rearrangement). Multiple agonists activate via GPCRs: thrombin (PAR-1, PAR-4), ADP (P2Y1, P2Y12), TXA2 (TP). Activation triggers granule release, phospholipase A2 generates TXA2 from arachidonic acid (COX-1 dependent), and inside-out signaling activates GP IIb/IIIa. Phosphatidylserine flips to outer membrane, providing surface for coagulation cascade assembly. Clopidogrel and ticagrelor block P2Y12; ticagrelor is reversible; clopidogrel is irreversible.

How does aspirin prevent clots?

Aspirin acetylates serine 529 in COX-1, irreversibly inhibiting prostaglandin synthesis in platelets. Platelets lack nuclei, so they can't synthesize new COX-1 — effect lasts platelet lifetime (7-10 days). This blocks thromboxane A2, reducing platelet activation/aggregation. Low-dose 81 mg/day is sufficient because portal circulation acetylates platelets before liver synthesizes new COX. Endothelial cells regenerate COX-1, preserving prostacyclin (PGI2). Used for secondary prevention of MI and stroke; primary prevention now controversial due to bleeding risk.

What causes thrombocytopenia?

Three mechanisms — decreased production, increased destruction, sequestration. Decreased production: bone marrow failure, leukemia, chemotherapy, alcohol, B12/folate deficiency, viral infection. Destruction: ITP (autoimmune), TTP, HIT (heparin-induced), DIC, drug-induced. Sequestration: hypersplenism (cirrhosis). Bleeding risk: spontaneous mucocutaneous bleeding < 50, severe < 10-20. ITP treated with steroids, IVIG, rituximab, TPO mimetics. Avoid platelet transfusion in TTP/HIT (worsens thrombosis).

What is heparin-induced thrombocytopenia (HIT)?

Paradoxical pro-thrombotic syndrome — IgG antibodies to heparin-PF4 complexes activate platelets via FcγRIIa, causing platelet consumption AND widespread thrombosis. Drop > 50% from baseline platelets 5-10 days after starting heparin (or sooner with prior exposure). 4T score risk-stratifies. Stop ALL heparin immediately, including line flushes. Use non-heparin anticoagulant (argatroban, bivalirudin, fondaparinux). NEVER transfuse platelets — fuels clotting. 30-50% develop venous or arterial thrombosis if untreated.

What's TTP and how is it treated?

Thrombotic thrombocytopenic purpura — deficiency of ADAMTS13 (a metalloprotease that cleaves ultra-large vWF multimers) leads to platelet-rich microthrombi in small vessels. Pentad: microangiopathic hemolytic anemia (schistocytes), thrombocytopenia, fever, neurologic symptoms, renal dysfunction. Acquired form has anti-ADAMTS13 antibodies. Untreated mortality > 90%. Treatment: urgent plasma exchange (removes antibodies, replaces ADAMTS13), corticosteroids, rituximab, caplacizumab (anti-vWF nanobody). Do not transfuse platelets — worsens thrombosis.

How are platelet function disorders evaluated?

PFA-100 (Platelet Function Analyzer) — high-shear test simulating in vivo conditions; prolonged in vWD, antiplatelets, thrombocytopenia. Light transmission aggregometry — gold standard, measures platelet response to multiple agonists (ADP, collagen, epinephrine, ristocetin). VerifyNow point-of-care for clopidogrel/aspirin response. Bleeding time obsolete due to poor reproducibility. Inherited disorders: Bernard-Soulier (GP Ib defect), Glanzmann thrombasthenia (GP IIb/IIIa defect), storage pool disease.